12-Month Real-World Data: IL-17 vs. b/tsDMARDs in PsA
I am sharing the 12 month results from PRO-SPIRIT, a multi-country phase IV real world study evaluating IL 17 inhibition versus 5 other b/tsDMARDs classes in psoriatic arthritis. Now Available in the Journal of Rheumatic and Musculoskeletal Disease Open: e.lilly/3MsseVC
Intended for HCPs
I’m sharing an analysis that explores the interchangeability of blood-based biomarkers and amyloid-PET criteria in identifying Alzheimer’s disease pathology. #MedSky #NeuroSky
Learn more about these latest findings: e.lilly/4aOMnx4
New Publication Available
I’m sharing new data from the ADapt study exploring clinical outcomes, symptom burden, and quality of life measures in patients with moderate-to-severe atopic dermatitis. Now published in the Journal of Dermatology and Therapy: e.lilly/4tB8jEp
We are sharing the latest science in dermatology focusing on key care gaps in health equity and emerging initiatives shaping patient care. Click here to view the full publication now available in the Journal of Dermatology and Therapy: https://e.lilly/3ZDnuzc
We are sharing the latest science in dermatology focusing on key care gaps in health equity and emerging initiatives shaping patient care. Click here to view the full publication now available in the Journal of Dermatology and Therapy: e.lilly/3ZDnuzc
New publication available
I am sharing the latest phase 3 results exploring comorbidity status on long-term disease control of Atopic Dermatitis with an IL-13 Inhibitor . Now published in the Annals of Allergy, Asthma, & Immunology: e.lilly/49OwW7B
Intended for HCPs
I’m sharing results from the TRAILBLAZER-ALZ 2 long-term extension of an amyloid-targeting therapy in early symptomatic Alzheimer’s disease. #MedSky #NeuroSky
Learn more about our latest findings: e.lilly/48ckkaR
New Publication Available
I am sharing the latest results of a phase 1 study exploring single vs. double injection of an IL23p19 in healthy patients. Now published in Advances in Therapy: e.lilly/3KEUofb
For HCPs
I’m sharing results from a randomized clinical utility study of P-tau217 testing impact on intended management of patients presenting with cognitive impairment. #MedSky #NeuroSky
Learn more about our latest findings: e.lilly/4o8teLh
Updated EMBER-3 Trial Efficacy Results
I'm sharing updated efficacy results from the EMBER-3 trial, a phase 3 trial investigating an oral SERD with or without a CDK4/6i in patients with ER+,HER2- advanced breast cancer.
Click here to access the publication: e.lilly/3MvMyVB
#BreastCancer #SERD
For HCPs
I’m sharing the latest results on long-term disease control in patients with moderate to severe Atopic Dermatitis – Now published in the journal of Clinical and Experimental Dermatology: e.lilly/48aYVie
#MedSky #DermSky
For HCPs
I'm sharing new data from the real-world effectiveness of a single versus a dual incretin receptor agonist on HbA1c and weight in patients with type 2 diabetes study, now published in Diabetes Therapy.
Click here to read the full study: e.lilly/3WNj1IP
#MedSky #EndoSky
Intended For HCPs
I’m sharing results from a secondary analysis of TRAILBLAZER-ALZ 2, a randomized clinical trial on posttreatment amyloid levels and clinical outcomes following amyloid-targeting therapy for early symptomatic Alzheimer’s disease. #MedSky #NeuroSky
Learn more about our latest findings: e.lilly/47YrWfO
Intended for HCPs
I'm sharing new research on the SURPASS-PEDS Phase 3 Study: Efficacy and Safety of an Incretin Receptor Agonist in Children and Adolescents with Type 2 Diabetes
Click here to read the full study: e.lilly/4quJybA
#MedSky #EndoSky
For HCPs
I'm sharing new research on therapeutic inertia in an insured population with type 2 diabetes in the United States: a retrospective cohort study
Click here to read the full study: e.lilly/4gQNEq3
#MedSky #EndoSky
New Publication
I’m sharing the results of an IL-13 inhibitor and its effect on head and neck Dermatitis and Erythema in ADvocate 1&2 and ADhere Trials. View the full publication here: e.lilly/45IJyuK
#MedSky #DermSky
New Publication
I am sharing the latest results of an IL-13 inhibitor on inflammatory biomarkers and clinical correlations in patients with moderate-to-severe Atopic Dermatitis. Now available in the Journal of Dermatology and Therapy. View full publication here: e.lilly/47HFkX1
#MedSky #DermSky
New Publication
I’m sharing the latest results from a biologic study in Atopic Dermatitis solely in patients with pigmented skin – Now published in the American Journal of Clinical Dermatology: e.lilly/3JGiWmO
New Publication in Alzheimer’s Disease
I’m sharing TRAILBLAZER-ALZ 6 now published in The Journal of Prevention of Alzheimer’s Disease: Modified amyloid-targeting therapy dose titration showed effects on imaging abnormalities (edema/effusions) and amyloid reduction at 18-months.
Learn more: e.lilly/4lNBAHq
#Neuroscience #NeuroSky
New Publicaton
I am sharing the latest results from a Phase 3 VIVID-1 study on bowel urgency response in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/3Uiqbnc
Click here to read the full study
I'm sharing new research on how body mass index, central adiposity, and weight loss impact the benefits of an incretin receptor agonist in HFpEF, now published in Journal of the American College of Cardiology.
Click here to read the full study: e.lilly/4fhnMCR
#MedSky #EndoSky
New Publication
I’m sharing 52-week outcomes on itch symptoms and sleep interference in moderate-to-severe atopic dermatitis from the ADvocate1 and ADvocate2 Phase 3 trials. View the full publication here: e.lilly/3ITBpvP
Intended for HCPs
I'm sharing new research comparing once-weekly Insulin and once-daily insulin in adults with type 2 diabetes who are currently treated with basal insulin
Click here to read the full study: e.lilly/3ZRHKhc
#MedSky #EndoSky
Intended for HCPs
Latest QWINT-4 Phase 3 Results Comparing Once-Weekly and Once-Daily Insulin in Adults with Type 2 Diabetes on Basal and Prandial Insulin — Now Published in The Lancet: e.lilly/4eQCxwa
#Diabetes
New Publication
I am sharing the latest results from a Phase 3 VIVID-1 study on fatigue outcomes in patients with Crohn’s disease. #MedSky #GISky
Click here to read the full publication: e.lilly/4072ul5
New Publication
I’m sharing new data from the ADjoin trial—a 2-year long-term extension study evaluating an IL-13 inhibitor in patients with moderate-to-severe atopic dermatitis. View the full results here: e.lilly/3GpizMw
#MedSky #DermSky
Intended for HCPs
I'm sharing new research from the ACHIEVE-1 Phase 3 study of a GLP-1 receptor agonist in early type 2 diabetes, now published in The New England Journal of Medicine.
Click here to read the full study: e.lilly/4lkZqKK
Intended for HCPs
I'm sharing new research on Weekly Fixed-Dose Insulin in Type 2 Diabetes without Previous Insulin Therapy, now published in NEJM!
Click here to read the full study: e.lilly/4nCNsOb
#MedSky #EndoSky
New Scientific Data
I'm sharing new scientific insights on a head-to-head study comparing dual and single incretin receptor agonists in obesity treatment: e.lilly/4dMJBto
#MedSky #EndoSky
BRUIN CLL-321 study is now published
I'm sharing the BRUIN CLL-321 study now out in JCO: The first randomized Ph3 study conducted exclusively in covalent BTKi-pretreated #CLL/SLL, evaluating a non-covalent BTKi vs idelalisib/rituximab or bendamustine/rituximab.
Full results and supplemental resources: e.lilly/4kA96k4
#LeuSky #OncSky
New Scientific Data
I’m sharing new results from SWITCH-1: A comparison of dose escalation of an incretin receptor agonist versus switching to another incretin receptor agonist among people with inadequately controlled type 2 diabetes.
Click here to read the full study: e.lilly/4jkBd6n
#MedSky #EndoSky
